GLP-1 Medications, Chronic Pain, and Mobility: An Evidence-Based Perspective from Physical Medicine & Rehabilitation

By Dr. Juliet Gaisey, MD

Board-Certified Physical Medicine & Rehabilitation

In daily clinical practice, many patients with chronic pain struggle to meaningfully participate in rehabilitation due to weight-related mechanical and metabolic limitations. While GLP-1 receptor agonists are most often discussed in the context of diabetes and obesity management, they raise an important rehabilitation-focused question:

Can GLP-1–based therapies indirectly improve chronic pain and mobility by reducing barriers to movement and functional recovery?

This article reviews the current evidence through a PM&R lens, with careful attention to what is supported and what is not.

Obesity, Chronic Pain, and Functional Limitation

The relationship between excess body weight and chronic musculoskeletal pain is well established. Obesity contributes to pain and disability through multiple mechanisms, including:

• Increased mechanical loading of weight-bearing joints

• Altered gait mechanics and balance

• Reduced endurance and activity tolerance

• Low-grade systemic inflammation

Higher BMI is strongly associated with knee osteoarthritis, low back pain, mobility disability, and worse functional outcomes over time. In rehabilitation settings, excess weight often limits participation in physical therapy and slows functional progress.

What GLP-1 Receptor Agonists Do and Do Not Do

GLP-1 receptor agonists are not analgesics and should not be presented as direct treatments for chronic pain.

Their established effects include:

• Clinically meaningful weight reduction

• Improved glycemic control

• Reduction in cardiometabolic risk

  
  

However, weight loss itself is a recognized modifier of musculoskeletal pain and function. Evidence demonstrates that even 5–10% weight loss is associated with:

• Reduced joint loading

• Improved pain in knee osteoarthritis

• Faster gait speed

• Improved physical function and activity tolerance

  
  

From a PM&R perspective, this matters because functional capacity, not pain scores alone, determines rehabilitation success.

Patient Selection Matters

The potential rehabilitation role of GLP-1 therapy is most relevant in patients with obesity-associated pain syndromes, such as:

• Knee or hip osteoarthritis

• Lumbar degenerative spine disease

• Generalized deconditioning

Mobility-limiting joint pain where excess weight clearly exacerbates symptoms

GLP-1 therapy is not appropriate or necessary for all chronic pain patients, and should be considered only when excess weight is a meaningful contributor to functional limitation.

Mechanisms Relevant to Pain and Mobility (Indirect Effects)

1. Reduced Mechanical Joint Loading

Biomechanical studies show that for every pound of weight lost, knee joint load is reduced by approximately four pounds per step during ambulation an effect that is clinically meaningful for patients with knee osteoarthritis.

2. Improved Rehabilitation Tolerance

Weight reduction is associated with improvements in gait speed, sit-to-stand performance, balance, and endurance key markers of independence, fall risk, and therapy participation.

3. Inflammatory Pathways (Emerging Evidence)

GLP-1 receptor agonists may influence inflammatory signaling and adipokine profiles. While this evidence remains emerging and should not be overstated, reductions in systemic inflammation associated with weight loss may contribute indirectly to symptom improvement in select patients.

What the Evidence Does Not Support

• GLP-1 medications are not indicated for chronic pain treatment

• They do not replace physical therapy, strengthening, mobility training, or behavioral interventions

• Weight loss alone does not resolve all pain syndromes

Best outcomes in PM&R occur when pharmacologic, rehabilitative, and behavioral strategies are integrated, not isolated.

A Rehabilitation-Centered Role for GLP-1 Therapy

In carefully selected patients, GLP-1 therapy may function as a rehabilitation-enabling adjunct by reducing mechanical barriers to movement, improving tolerance for therapy, and supporting sustained engagement in mobility-focused care.

GLP-1 therapy may reduce barriers to rehabilitation, not replace it.

Clinical Takeaway

From a physiatry perspective, GLP-1 receptor agonists should be viewed as supportive tools, not cures. When used thoughtfully and under physician supervision, they may improve pain-related function by addressing weight-driven contributors to mobility limitation as part of a broader, rehabilitation-centered care plan.